Published in Clin Interv Aging on January 01, 2008
Mandibular inferior cortical bone thickness on panoramic radiographs in patients using bisphosphonates. Oral Surg Oral Med Oral Pathol Oral Radiol (2015) 0.81
Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis. Patient Prefer Adherence (2010) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser (1994) 17.37
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res (2007) 14.84
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med (2004) 8.86
Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med (2007) 7.38
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Risk of new vertebral fracture in the year following a fracture. JAMA (2001) 6.17
Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA (2005) 5.95
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59
Cellular and molecular mechanisms of action of bisphosphonates. Cancer (2000) 3.57
Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc (2006) 3.41
Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res (1999) 3.08
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res (1996) 2.61
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res (1996) 2.59
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin (2005) 2.57
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol (2006) 2.52
Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev (2002) 2.49
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA (1997) 2.46
Alendronate and atrial fibrillation. N Engl J Med (2007) 2.00
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone (2007) 1.97
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone (2007) 1.94
Renal failure with the use of zoledronic acid. N Engl J Med (2003) 1.89
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab (2006) 1.88
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol (2003) 1.80
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin (2008) 1.79
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust (2005) 1.76
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther (2007) 1.73
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int (2003) 1.65
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int (2002) 1.61
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) (2000) 1.59
Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun (2005) 1.56
Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med (2006) 1.55
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract (2006) 1.46
Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev (2002) 1.44
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab (2007) 1.43
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin (2005) 1.33
Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int (2007) 1.21
An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol (2006) 1.20
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol (2008) 1.18
Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. Neth J Med (2002) 1.11
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int (2005) 1.09
Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthritis Rheum (2005) 1.09
A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin (2007) 1.08
Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf (2007) 1.08
The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. Oncologist (2002) 1.06
American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis. Endocr Pract (2001) 1.05
Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone (2004) 1.03
Zoledronic acid-induced IPP/ApppI production in vivo. Life Sci (2007) 0.98
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin (2005) 0.98
Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials. Int J Clin Pract (2006) 0.97
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin (2008) 0.96
Zoledronic acid: a review of its use in patients with advanced cancer. Drugs (2004) 0.96
Economic burden of osteoporosis-related fractures in Medicaid. Value Health (2007) 0.95
Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin (2007) 0.92
Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone (2004) 0.89
Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin (2004) 0.84
Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab (2003) 0.84
Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med (2007) 0.84
What is the role of DXA, QUS and bone markers in fracture prediction, treatment allocation and monitoring? Best Pract Res Clin Rheumatol (2005) 0.83
Ocular side effects associated with bisphosphonates. Drugs Today (Barc) (2003) 0.82
Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther (2000) 0.82
Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis (2007) 0.81
Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate. Drugs (2006) 0.81
Drug-induced ocular inflammatory diseases. Drugs Today (Barc) (2007) 0.80
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. Maturitas (2006) 0.78
Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data. Curr Med Res Opin (2008) 0.78
The role of calcium in osteoporosis drug therapy. J Womens Health (Larchmt) (2005) 0.78
Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates. Ann N Y Acad Sci (2007) 0.77
Weak and feeble bones no more: the National Osteoporosis Foundation speaks out. J Womens Health (1998) 0.77
Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med (2007) 0.76